Times Up: Hospitals and the 340B Markup Program Need Reforms

Why It Matters

Unrestricted 340B mark‑ups inflate prescription costs for patients and taxpayers, undermining the program’s safety‑net purpose. Reform could lower drug prices and ensure savings reach the low‑income populations the law intended to protect.

Key Takeaways

• 340B lets hospitals buy drugs at pennies per dose.
• Hospitals mark up 340B drugs by thousands, pocketing profits.
• Program generates roughly $65 billion revenue stream nationwide.
• Minnesota hospitals earned $1.34 billion profit from 340B in 2024.
• Senate and House hearings signal bipartisan push for reform.

Pulse Analysis

The 340B program was created in 1992 to enable safety‑net hospitals to purchase outpatient drugs at deep discounts, passing savings on to vulnerable patients. Over time, the lack of price‑cap oversight has allowed many institutions to treat the discount as a wholesale procurement tool, buying medicines for a few cents and billing insurers at market rates. This structural loophole now fuels a $65 billion, oversight‑free revenue stream, with state‑level case studies—such as Minnesota’s $1.34 billion profit in 2024—illustrating the scale of the issue.

Congressional attention has surged, with the Senate HELP committee in October 2025 and the House Energy and Commerce Committee in March 2026 holding hearings that underscore bipartisan alarm. Lawmakers are debating reforms ranging from mandatory pass‑through of savings to patients, to caps on allowable mark‑ups and enhanced reporting requirements. Political dynamics are favorable for change because the program’s exploitation affects both Democratic and Republican constituencies: high drug costs burden taxpayers, while hospital profit motives clash with public expectations of affordable care.

If reforms materialize, the ripple effects could be significant. Insurers would face reduced claim costs, potentially lowering premiums for employers and individuals. Patients, especially those qualifying for low‑income assistance, would finally see the intended price reductions, improving medication adherence and health outcomes. Moreover, curbing the profit incentive could redirect hospital resources toward genuine community health initiatives, aligning the 340B program with its original public‑health mission and restoring confidence in federal drug‑pricing policies.